ABSTRACX. Total body and renal elimination of L-alloisoleucine was assessed after oral loads (0.57 mmollkg body wt) in four healthy subjects and in five patients with maple syrup urine disease (MSUD) of different degrees of severity. As judged from the fictive initial concentration, L-alloisoleucine is distributed evenly in the total body water space. In the controls, estimated half-time of total elimination was 9.2 2 2.2 h (n = 4). In the MSUD patients, it ranged from 26 h (mild variant) to about 8 d (classical type). Because of its low renal clearance rate, L-alloisoleucine was cleared through ketomethylvalerate to >99% in normals and to at least 73% in the MSUD patients. Assuming small variation in the losses of ketomethylvalerate through L-isoleucine formation and through renal excretion, this test allows ranking of MSUD patients with regard to their residual in vivo branched-chain 0x0-acid dehydrogenase activity. (Pediatr Res 30: 430-434, 1991) 
therefore, seems to be confined primarily to metabolic degradation via the so called "R-pathway" of ile metabolism (15) . Accordingly, "natural" allo blood levels related to simultaneous ile levels were found to correlate with the residual in vitro activity of BCOA dehydrogenase (10) .
Besides these more general findings, little is known of the quantitative aspects of in vivo a110 catabolism in man (4) and there is, to our knowledge, only one former report on a110 loading experiments (6) .
Here we report on clearance rates after oral loads of allo in four healthy subjects and five patients with MSUD of different degrees of severity. Two questions were asked in the present study: 1) To what extent does the a110 catabolism differ between normals and MSUD patients in vivo and 2 ) does the a110 elimination constant provide a better in vivo indicator of the severity of the disease than the "natural" plasma allo/ile ratio reported previously ( I O)?
MATERIALS AND METHODS

Chemicals.
Unless otherwise noted, all chemicals were purchased in the highest available purity from Merck (Darmstadt, Germany) or Sigma (Deisenhofen, Germany). Allo was obtained from Bachem (Heidelberg, Germany). As checked by amino acid and 2-0x0 acid analysis (see below), it contained less than 1.5% ile and no KMV.
Alloisoleucine loads. In general, probands and patients received 0.57 mmol allo/kg body weight p .~. around 1300 h. Venous blood was collected in a heparizined syringe just before the load (control value) and thereafter in varying time intervals as indicated in the figures. In four of the loading experiments, spontaneous urine was collected in parallel with the blood samples to allow an estimation of renal clearance rates. The study had been approved by the Ethical Committee of the Diisseldorf Medical Faculty.
Assays. BCAA concentrations in body fluids were measured on an automatic amino acid analyzer (LC 6000 or LC 6001; Biotronic, Munich, Germany). In general, the short program for BCAA of Benson et al. (16) as modified by Schadewaldt et al.
(2) was used. For the estimation of the BCOA, the respective quinoxalinol derivatives were analyzed by reversed phase HPLC using 2-oxohexanoate as an internal standard as described previously (17) . Creatinine was measured enzymatically (18) on a Hitachi 704 analyzer (Boehringer, Mannheim, Germany). BCOA dehydrogenase activity in intact skin fibroblasts was assayed in microtest plates as described previously (19 (17) . All decay: The residuals were randomly and evenly distributed over these patients have been described previously (10, 20, 21) . the time period ( Figs. 1 and 2 ). The residual x2, as provided by Four healthy adults with normal body weight served as con-the software, allows comparisons of the goodness of fit between trols. Matched controls (i.e. healthy children) were not available the different oral loading experiments. No consistent changes in for the experiments.
the plasma levels of the other BCAA were observed in our a110 Calculations. The time course of the decrease of the a110 plasma loading experiments. levels, starting with the data 5-8 h postload, was subjected to
The estimates of k, are given in Table 1 . In normal controls, pharmacokinetic analysis using a one-compartment model with mean k, was 1.89 + 0.43 d-l, which corresponds to a normal single exponential decay. The results were estimates of k, and plasma half-time of 9.2 k 2.2 h. In MSUD patients, the decline Yo. In MSUD patients, a first calculation was made for estimating of a110 plasma levels was considerably delayed and was related k,. The preload a110 levels in the patients were then used for to the severity of the disease (Table 1 and Fig. 2 ). Estimated calculation, with the k, estimate, of corrected postload levels. plasma half-times ranged from 26 h in variant AC to about 8 d They yielded, in a second calculation, a rough estimate of Yo in the classic type patient TA. also for the patients. We used the PC-based ENZFITTER softThe total body clearance (t.b.cl.) in the control subjects was ware package (22) , which applies Marquardt's enhanced algo-calculated from k, and actual volume of distribution. Because in rithm to the untransformed data. The software, with automatic MSUD patients the Y o is subject to larger experimental errors, guess of initial estimates and with simple and robust weighting, t.b.cl. has been calculated as t.b.cl. = k. [(0.535 . kg + 0.223.
arrived at stable estimates after three to four iterations. Further kg0.762)/(7 1.84.
~m ' . '~~) ] . 1.73. 10.000. This procedure aspharmacokinetic calculations followed standard procedures (23) . sumes even distribution of a110 in the total body water (see above) Body surface was calculated with the equation of Dubois and and combines the equations for surface area (24) and body water Dubois (24) .
in children (26) . The estimates of the t.b.cl. in controls and Renal clearance rates (CR) were approximatively estimated patients are given also in Table 1 . using a modified clearance formula:
Renal clearance of BCAA and BCOA. The actual clearance data, as obtained in the loading experiments in two normal
controls, are given in Table 2 . Standardized to 1.73 m2, the renal where [PI, was the metabolite concentration in and V, the volume of the urine collected between two successive time points t l and t2, and [PI,, and [PIt, were the concentrations in plasma samples withdrawn at t l and tz after start of the a110 load. The time intervals chosen were the same as in the main study.
Results are given as mean t-SD, unless stated otherwise (Table  1) .
RESULTS
Distribution of allo.
The apparent volume of distribution was compared with total body water data for adults (related to weight, sex, and age groups) in the study by Edelman and Leibman (25) and with the body weight-related function of Gladtke (26) for children and juveniles. The experimental estimates of volume of a110 clearance was 19 and 8 mL/h, respectively. These values correspond to renal elimination constants of 0.012 and 0.004 d-', respectively, which is 0.2 to 0.7% of the total k, of allo. The renal clearance of a110 in two MSUD patients under conditions of good metabolic control was found in the same order of magnitude (Table I) .
Fate of allo carbon. Allo-induced changes in the plasma content of KMV were measured in two control and in two MSUD subjects (data not shown). A reliable method for separate quantification of the (S)-(from ile) and (R)-enantiomer (from allo) is not yet available (10) . Total KMV levels increased within a few hours, plateaued for hours or even days, and then gradually declined. As related to controls, height and duration of the plateaus as well as the time-dependent decline of KMV in MSUD corresponded rather well with the apparent severity of the disease in the affected patients.
EBux ofallo through KMV. The total body clearance of a110 (Table l) , these findings indicate that in MSUD patients from 73% to more than 96% of an a110 load leaves the body through formation of KMV and its subsequent renal and metabolic handling. In controls, this fraction exceeds 99%. 
DISCUSSION
In the study presented here, we have provided estimates for the in vivo catabolism of a110 in normal subjects and in patients with MSUD. These data confirm and extend a previous study of Snyderman et al. (6) , who found the allo plasma half-lives of 5.5 and 7.5 d, respectively, in two patients with classic MSUD.
Our calculations are based primarily on the time course of a110 plasma concentrations after an oral a110 load. At the latest, 5-8 h after oral load, the plasma levels of a110 faithfully followed a single exponential elimination function. The volume of distribution was estimated using this function and was found to be The in vivo estimation of residual BCOA dehydrogenase activity by loading with the nonprotein amino acid allo offers considerable advantages in the evaluation of MSUD patients, because problems of pool size and protein synthesis are efficiently minimized, without recourse to stable isotope studies. There is ample evidence in the literature (7) that leucine and/or 2-0x0 isocaproic acid are the prime toxic metabolites in MSUD. This will exclude experimental leucine tolerance studies for medical as well as for ethical reasons. Our present study has demonstrated that a safe and efficient alternative method is now available.
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* Data refer to the experiments shown in Figure 1 and Table I . Rates are standardized to 1.73 m' body surface. They were estimated on the basis of the plasma concentrations and the renal excretions in the sampling periods during the 1st and 24th h after a110 ingestion. Timedependent changes of clearance rates were not observed. Total clearance represents the sum of metabolites that were excreted within 24 h after the load. Urinary concentrations of BCOA other than KMV were too low to be evaluated.
close to the nominal total body water space in all individuals. This is not unexpected, because the BCAA do not bind to plasma proteins and are normally not concentrated in or excluded from cells or tissues (4, 7, 27) . The elimination of allo from plasma therefore reflects elimination from total body in the sense of a one-compartment model. These considerations do not apply to the BCOA, for which considerable plasma protein binding has been demonstrated (7, 28) and for which plasma and muscle levels do differ (29, 30). For these reasons and because the renal BCOA clearance is concentration dependent (141, a further kinetic analysis (modeling) was not attempted with the present data.
Renal excretion of allo plays almost no role in its elimination from the body. We found this contribution to be less than 1 % of total body clearance in normal controls, 4% in MSUD variant case GU, and still only 27% in the classic MSUD case TA. It thus appears that MSUD patients lose most of an oral load of allo through formation of KMV and subsequent reactions, e.g. renal loss of KMV. Our data give no hint to the real extent of formation of ile from allo via (R)-and (S)-KMV. We can only surmise that this route, under the conditions of our loading test (0.570 mmol per kg body wt at times with more or less normal BCAA plasma levels), bears no major significance, because consistent increases of plasma ile levels could not be seen. In recent papers, we have discussed these points with reference to a socalled "metabolic trap" model of allo metabolism (2, 10) .
The rather close correlation between k, of allo and clinical type in MSUD patients strongly suggests that the residual activity of BCOA dehydrogenase is the rate-limiting step of all the Rpathway, at least in MSUD patients. Therefore, the k, of allo as determined from sequential plasma levels after an oral allo load appears to be a better indicator of clinical type than the residual in vitro BCOA dehydrogenase activity or the previously reported plasma allolile ratio (10) and (Table 1) : The parameter k, is much better defined, and the spread of parameter values across patients of different clinical types is more pronounced. Closer scrutiny of discrepancies between in vivo and in vitro data, which are also seen with in vivo 13C-leucine studies ( 3 l), may contribute in the future to a better understanding of the pathophysiology of MSUD.
We are presently trying to find out whether the k, estimates in different patients may vary significantly over prolonged periods of time. Such data would also contribute to the question of possible regulatory changes of the residual in vivo BCOA dehydrogenase activity in different types of MSUD, e.g. in the stillenigmatic intermittent cases (7).
